Adding age and genetic risk to PSA test could improve screening for prostate cancer

BMJ 2012; 345 doi: http://dx.doi.org/10.1136/bmj.e7467 (Published 6 November 2012)
Cite this as: BMJ 2012;345:e7467

Get access to this article and all of bmj.com for the next 14 days

Sign up for a 14 day free trial today

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Zosia Kmietowicz
  1. 1London

Targeting tests for prostate cancer at the men most likely to develop the disease could halve the number needed to be screened, reduce overdiagnosis, and potentially save the NHS millions of pounds, suggests research.

With funding from Cancer Research UK, researchers from London and Cambridge developed a model to estimate the cost and quality adjusted life years (QALYs) of a personalised screening programme compared with an age based screening strategy using data from English cancer registries and the ProtecT study (http://www.hta.ac.uk/1230) into the treatments for clinically localised prostate cancer.

Both strategies used the prostate specific antigen test …

Get access to this article and all of bmj.com for the next 14 days

Sign up for a 14 day free trial today

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

Article access

Article access for 1 day

Purchase this article for £20 $30 €32*

The PDF version can be downloaded as your personal record

* Prices do not include VAT

THIS WEEK'S POLL